Introduction

▼
The causative agent of acquired immune defi ciency syndrome (AIDS) is the human immunodefi ciency virus type 1 (HIV-1). During the past 3 decades, the combination of antiretroviral drugs in HAART (highly active antiretroviral therapy) regimens has transformed the management of HIV infection from a fatal disease to a manageable chronic condition [ 1 , 2 ] . However, resistance to marketed anti-HIV drugs is increasing at an alarming rate. Thus, there is a need to develop new agents which work by diff erent mechanisms. In this regard, there has been considerable interest in HIV integrase (IN) function as an attractive alternative target that may lead to the next generation of anti-HIV drug [ 3 , 4 ] . HIV-1 integrase is one of the 3 most important enzymes required for viral replication. It catalyzes the insertion and the integration of the proviral DNA into the genome of the host cell in 2 steps: 3′-processing (3′-P), the endonucleolytic sequencespecifi c hydrolysis of 3′-ends of the viral cDNA, and strand transfer (ST), the ligation of the viral 3′-OH cDNA ends to the phosphate backbone of the host DNA acceptor. This enzymatic process is dependent on an active site containing dual Mg 2 + metal ions held in place with a highly conserved triad of carboxylate amino acid residues (asp64/asp116/ glu152) commonly referred to as a DD(35)E triad tively. A docking study using the later crystallographic data available for PFV integrase including its complexes with Mg 2 + and raltegravir, showed that the designed compounds bind into the active site of integrase such that carboxylic and hydroxyl groups of 4-hydroxyquinoline-3-carbohydrazide chelate the Mg 2 + ion. Interestingly, all of the synthesized compounds were found to present no signifi cant cytotoxicity at concentration of 100 μM. Therefore, these compounds can provide a very good basis for the development of new anti-HIV-1 agents.
Hajimahdi Z et al. Anti-HIV activity of 4-Hydroxyquinolines … Drug Res 2013; 63: [192] [193] [194] [195] [196] [197] antiretroviral agents [ 13 -16 ] . On the other hand, 4-quinolone-3-carboxylic acid derivatives are attractive in anti-HIV-1 drug discovery due to their extremely versatile nature, well-known biochemical properties and having no signifi cant cytotoxic eff ects [ 17 , 18 ] . Based on these facts supported by literature and as a part of our research program aimed at discovering new anti-HIV-1 agents, we designed a novel noncytotoxic class of 4-hydroxyquinoline-3-carbohydrazide derivatives with various substituted aromatic moiety by integration of fragments of salicylhydrazide and 4-quinolone-3-carboxylic acid. Actually, according to HIV-1 integrase inhibitors structure activity relationship, the adjacent carboxylic and hydroxyl groups on 4-hydroxyquinoline-3-carbohydrazide could serve as the metal binding pharmacophore. Furthermore, the aryl group might serve as the pharmacophore to interact with the hydrophobic binding surface of the IN. We also performed docking studies to predict the interaction of new synthesized compounds into the active site of integrase and their probable mechanism of action.
Material and Methods
▼
Materials
All chemicals, reagents and solvents used in this study were purchased from Merck AG and Aldrich Chemical. Melting points were determined with a Thomas-Hoover capillary apparatus. A Synthos 3 000 microwave oven (Anton Paar, Austria) was used for synthesis of compounds. Infrared spectra were acquired using a Perkin Elmer Model 1420 spectrometer. A Bruker FT-500 MHz instrument (Brucker Biosciences, USA) was used to acquire 1 HNMR spectra with TMS as internal standard. Chloroform-D and DMSO-D 6 were used as solvents. The mass spectral measurements were performed on an 6410 Agilent LCMS triple quadrupole mass spectrometer (LCMS) with an electrospray ionization (ESI) interface. Microanalyses, determined for C and H, were within ± 0.4 % of theoretical values.
Preparation of diethyl 2-((phenylamino)methylene) malonate (3)
A mixture of aniline (0.9 ml, 10 mmol) and diethyl ethoxymethylenemalonate (EMME) (2 ml, 10 mmol) was heated at 120 °C for 1 h. The reaction mixture was cooled to room temperature. The solid thus formed was taken in n-hexane and stirred for 15 min and fi ltered to aff ord compound 3 . Yield, 62 %; white powder; mp 44-45 °C [ 19 ] ; IR (KBr disk): υ (cm 
Preparation of ethyl 4-hydroxyquinoline-3-carboxylate (4)
A diphenyl ether solution of 3 containing catalytic 2-chlorobenzoic acid was heated by microwave irradiation (250 °C, 180 W) for 2 h. The reaction mixture was cooled to room temperature and added n-hexane (50 ml) and stirred for 15 min, the precipitated solid was fi ltered and dried to get compound 4 . The fi nal product was crystallized in ethanol. Yield, 75 %; cream powder; mp 261-262 °C [ 19 ] ; IR (KBr disk): υ (cm 
Preparation of 4-hydroxyquinoline-3-carbohydrazide (5)
A mixture of 4 (2 g, 4.5 mmol) and hydrazine hydrate (6 ml, 45 mmol) in DMF (5 ml) was stirred at room temperature for 12 h. Completion 
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of the reaction was monitored by TLC. After reaction completion, water (50 ml) was added and the solid product obtained was fi ltered, washed with water to give 5 . General procedure for preparation of 4-hydroxy-N′-(4-substituted-benzoyl) quinoline -3-carbohydrazide (6a-e)
A mixture of 5 (0.3 g, 1.5 mmol), 4-substituted benzoyl chlorides (0.2 ml, 1.5 mmol) and a catalytic amount of Na 2 CO 3 (0.05 g, 0.5 mmol) was dissolved in dry DMF (10 ml) and stirred at room temperature for 16 h. The reaction mixture was slowly poured over crushed ice and kept for 2 h. The solid thus separated out was fi ltered, washed with water and recrystallized from ethanol to give compounds ( 6a-e ) (Yield, 30-40 %).
N′-Benzoyl-4-hydroxyquinoline-3-carbohydrazide (6a)
Yield, 40 %; white powder; mp 288-290 °C (decomposed); IR (KBr disk): υ (cm 
2-(4-Hydroxyquinoline-3-carbonyl)-N-(4-methoxyphenyl) hydrazine carboxamide (7e)
Yield, 35 %; white powder; mp 265-266 °C; IR (KBr disk): υ (cm 
In-vitro anti-HIV and cytotoxicity assays
The inhibitory eff ect of compounds against HIV-1 was studied by single cycle replication assay as previously described [ 20 ] . In brief, Hela cells (6 × 10 3 per well of 96-wells plate) were infected with single cycle replicable HIV NL4-3 virions (200 ng P 24 ) in the presence of diff erent concentrations of compounds (1, 10 and 100 μM). Addition of compounds to the cells environment was simultaneous with viral infection. The supernatants were collected 72 h postinfection and evaluated for P 24 antigen load by capture ELISA (Biomerieux, France). The inhibition rate ( %) of P 24 expression was calculated. The cellular toxicity was evaluated by XTT (sodium 3-[1(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid) proliferation assay (Roche, Germany) according to the kit instruction [ 21 , 22 ] . The HIV replication assay plates were directly considered for cytotoxicity assay after determination of P 24 load.
Molecular modeling (docking) studies
The active compounds were selected for docking studies against HIV-1 IN. 3OYA is used for binding mode analysis of HIV-1 IN inhibitory activity. All the compounds were built using ChemDraw and subsequently minimized. The protein structure was prepared for docking using AUTODOCK Tool. Docking was performed by AutoDock 4.0 program, using the implemented empirical free energy function and the Lamarckian Genetic Algorithm (LGA) [ 23 ] . Co-crystallized ligand and all water molecules were removed from crystal protein (3OYA) while magnesium ions (Mg 2 + ) at the active site of HIV-1 IN were maintained.
Polar hydrogens were added and non polar hydrogens were merged, fi nally Kallman united atom charge and atom type parameter was added to 3OYA. Grid map dimensions (20 × 20 × 20) were set surrounding active site. Lamarckian genetic search algorithm was employed and docking run was set to 50.
Results and Discussion
▼ Chemistry
The target 4-hydroxyquinoline-3-carbohydrazide derivatives were synthesized via the route outlined in • ▶ Fig. 2 . The GouldJacob cyclization reaction is regarded as the most fundamental and versatile method to form the core structure of 4-hydroxyquinoline-3-carboxylate [ 19 ] . The compounds 4-hydroxy-N′-(4-substituted-benzoyl) quinoline-3-carbohydrazides 6a-e and N-(4-substituted-phenyl)-2-(4-hydroxyquinoline-3-carbonyl) hydrazinecarboxamide 7a-e were prepared according to GouldJacob cyclization reaction, starting from aniline in 4 steps. Condensation of aniline with ethoxymethylene malonate diethyl ester (EMME) yielded diethyl 2-((phenylamino)-methylene) malonate 3 . 
Biological evaluation
The anti-HIV activity of the all compounds was measured by determining their ability to general inhibition of the replication of HIV-1 in Hela cells cultures. For comparative purposes, nucleoside reverse transcriptase inhibitor, AZT, was assayed in the same cells. All synthesized compounds were also tested for their cytotoxicity by MTT assay. As shown in • ▶ Table 1 , all synthesized compounds displayed no signifi cant cytotoxicity at concentration of 100 μM. Most of the tested compounds produced inhibitory eff ects at 100 μM concentration with a percentage ranging from 5 to 32 %. However, in all cases, the measured activities were lower than that of AZT. These results indicated that chelation of the 2 Mg 2 + cations by adjacent carboxylic and hydroxyl groups as chelation motif are not strong enough to allow for a strong anti-HIV-1 activity by these compounds. 4-Hydroxyquinoline-3-carbohydrazide compounds 6a-e containing 4-substituted benzoyl groups as aromatic ring, showed moderate activity against HIV ranging from 21-32 %, except for compound 6c , which exhibited 8 % inhibition rate. However, compounds 7a-e having 4-substituted N-phenyl moiety displayed no considerable anti-HIV activity (0-5 %) except for compound 7e (having methoxy substitution) with inhibition rate of 28 %. The structural diff erence between 6a-e and 7a-e lies in the incorporation of N-H between substituted phenyl ring This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
and second carbonyl group in compounds 7a-e . These results demonstrated that specifi c orientation of phenyl ring to the chelator group is a requirement for high anti-HIV-1 activity. According to our results compound 6d having methyl group at para position of phenyl ring showed the highest anti-HIV-1 activity (32 %) among the synthesized compounds. These fi ndings conform to the common pharmacophore of HIV-1 integrase inhibitors in which a hydrophobic aromatic group with a specifi c spatial arrangement to a chelator is a required structural determinant.
Molecular modeling studies
Docking studies were performed to predict the binding mode of designed compounds and to rationalize the observed structure activity relationships. Based on these results, a mechanism of inhibition for these compounds is proposed. Due to the lack of HIV-1 IN/DNA experimental structures, the building of a reliable model is essential for predicting docking of integrase inhibitors. Fig. 3 ). The displaced 3′-adenosine terminal base (A17) was involved in a π-stacking interaction with the quinoline ring. The p -substituted-phenyl group fi tted within a tight pocket formed by cytosine 16 (C16), guanine 4 (G4). Further docking study revealed that active compounds ( 6d and 7e ) occupied same space near to Mg 2 + ions as Raltegravir ( • ▶ Fig. 4 ).
These docking results were in agreement with the common structure activity relationships of HIV-1 integrase inhibitors.
Conclusions
▼
In conclusion, we have designed and synthesized a novel class of 4-hydroxyquinoline-3-carbohydrazide derivatives by merging 2 well-known anti-HIV-1 scaff olds, salicylhydrazide and 4-quinolone-3-carboxylic acid. The major signifi cance of this work as compared to previous reports on salicylhydrazide structure is that the synthesized compounds displayed no considerable cytotoxicity in cells cultures. So, this novel scaff old is suitable for the development of new hits. Compounds 6d and 7e were found to be the most active in cell based anti-HIV assay with inhibition rates of 32 and 28 % at concentration of 100 μM, respectively. The molecular modeling studies suggested that the anti-HIV activity of these compounds might involve a metal chelating mechanism.
